Succinylated Gelatin for Prevention of Fluid Retention in Patients With Breast Cancer Receiving Docetaxel Chemotherapy

A Randomized, Phase II Study of Succinylated Gelatin for Prevention of Fluid Retention in Patients With Breast Cancer Receiving Docetaxel Chemotherapy

Breast cancer patients who received docetaxel chemotherapy were randomly divided into two groups; experimental group: the patients received intravenous infusion of succinylated gelatin one day before and on the day of chemotherapy, 500ml each time, once per day; control group: observation. Primary endpoint: total incidence of fluid retention. Secondary endpoints: severity and duration of fluid retention, change in quality of life score.

Inclusion Criteria:

• Signed informed consent
• Age ≥18 years
• Diagnosed with breast cancer
• ECOG 0-2
• Received chemotherapy with docetaxel

Exclusion Criteria:

• Existed peripheral edema, ascites and pleural or pericardial effusion
• Serum creatinine exceeds 1.5 times of the upper normal limit
• Total serum bilirubin exceeds 1.25 times of the upper normal limit, or ASAT exceeds 2 times of the upper normal limit